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Prostate focal lesionsAbstract Objectives: Assessing the value of Mp-MRI with PI-RAD2.0 in distinguishing between
malignant and benign prostatic lesions.
Patients & methods: 55 patients with suspicious prostatic lesions underwent PR examination, PSA
tests, TRU/S, and Mp-MRI prostate. Mean age was 62 years and imaging data were correlated with
histopathological data.
Results: Histopathology results revealed 38 malignant lesions and 17 were benign. DWI showed
signiﬁcant restriction with low ADC value, 0.89 ± 0.24 lm2/ms in 30 PZ lesions that diagnosed
to be likely malignant, (3–5 score) and 7 benign lesions showed no diffusion abnormality with
ADC values, 1.34 ± 0.21 lm2/ms which were statistically signiﬁcantly higher than those of malig-
nant lesions (P< 0.001). Of the 18 TZ lesions, T2 WI diagnosed 7 to be likely malignant (score 3–5)
and 11 were benign (1–2 score). DCE-MRI revealed positive results in 28 PZ and 8 TZ lesions. Add-
ing DCE-MRI to DWI and T2WI score in equivocal lesions raises its score from 3 to 4 in 6/9 lesions
that aid in malignant lesions diagnosis. Negative enhancement was noted in 9 PZ and 10 TZ benign
lesions (ve).
Conclusion: Multi-parametric MRI with PI-RAD V2 scoring system was proved to be non invasive
and accurate tool for distinguishing between malignant and benign prostatic lesions.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).ohamed
Table 2 Gleason score at biopsy for 38 malignant lesions.
Tumor Gleason score at biopsy* No. of lesions (%)
6 13 (34.2%)
7 12 (31.5%)
8 8 (21%)
9 3 (7.8%)
10 2 (5.2%)
* TRUS Biopsy.
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Prostate cancer is the 3rd leading cause of death and is the
most common genitourinary malignancy in men (1). Advances
in MRI show promise for improved detection and characteri-
zation of prostate cancer, using a multiparametric approach,
which combines anatomical and functional data (2). The mul-
tiparametric (Mp-MRI) approach using three different tech-
niques, T2-weighted (T2W) MRI, diffusion-weighted imaging
(DWI), and dynamic contrast-enhanced MRI (DCE-MRI))
can improve the diagnostic accuracy (3). The European Soci-
ety of Urogenital Radiology (ESUR) has called a panel of
experts and published a guideline providing recommendations
for the performance of mp-MRI investigations and a struc-
tured reporting scheme named Prostate Imaging Reporting
and Data System (PI-RADS) in February 2012 (4). The Major
goals of PI-RADS are to allow comparison of inter-observer
interpretation variability; to enhance communication with clin-
icians in a uniform way; to facilitate quality assurance and
research; and to improve patient outcome (5). The PI-RADS
scoring committee of the American College of Radiology
(ACR) and the European Society of Urogenital Radiology
(ESUR) prostate MRI working group have diligently devel-
oped a revised version called PIRADS 2.0 which was made
public in early 2015. PI-RADS 2.0 provides extensive informa-
tion on how to acquire, interpret, and report Mp-MRI of the
prostate (6). The speciﬁc aims of PI-RADS 2.0 were to estab-
lish guidelines for minimum acceptable technical parameters
for prostate Mp-MRI, to simplify and standardize the termi-
nology and content of Mp-MRI reports, and to develop assess-
ment categories that summarize the levels of suspicion or risk
of having signiﬁcant prostatic cancer. PI-RADS 2.0 is intended
to be a ‘‘living” document that evolves as clinical experience
and scientiﬁc validation data accrue (7).
This study aimed to assess the value of Mp-MRI with PI-
RAD 2.0 scoring system in differentiation between malignant
and benign prostatic lesions.
1.1. Patients and methods
During the period from May 2014 to October 2015, 55 patients
referred to radiodiagnosis department from urology Depart-
ment and their ages ranged between 51 and 79 years
(Mean =±62 years). The patient’s clinical diagnosis was sus-
picious prostatic nodule that felt during digital rectal examina-
tion. All patients underwent, PR examination, PSA tests, MRI
examination of the prostate with PI-RAD 2.0 scoring system
and TRU/S examination with biopsy. Written informed con-
sent was obtained from each patient and this work was
approved by local research ethics committee of our hospitals.Table 1 Analysis of the ﬁnal diagnosis of the 55 patients
according to the histopathologic results.
Histopathology No of lesions Percentage (%)
Adenocarcinoma 38 69.1
Benign prostate hypertrophy 11 20
Focal adenoma 4 7.2
Prostatitis 2 3.6
Total 55 1001.2. Exclusion criteria
Twelve patients were excluded from this study: – Five patients
had contraindications for MRI examination and contrast-
medium injections (3 with renal impairment, 1 claustrophobic
and 1 with cardiac pacemakers). Two patients rejected MR
examination and 3 refused to undergo the biopsy, also 2
patients with previous prostatic surgery were excluded from
this work.
1.3. MRI techniques
MRI examinations were done on 1.5 Tesla MRI (Gyroscan,
Philips, Netherland) unit with body coil coupled to endorectal
coil in the supine position, and the protocol was as follows:
T2WI and T1WI Axial and coronal, (TR, 5029, TE,100)
and (TR500, TE, 15), FOV, 350, slice thickness 3 mm and
interval, 0.3 mm. DCE-MRI Gad DETPA (gadolinium-Diethy
lenetriaminepenta-acetic acid) dose of 0.2 mmol/kg (maximum
dose 15 mmol) injected IV at a rate of 3 mL/s and Post Gad
study were taken at the early and delayed phases (after 2
min to assess enhancement pattern and delayed after 5 min
to assess washout). DWI with ADC values measurements: –
DW images obtained at b0, 500, 1000 s/mm2 gradients. (TR,
1570 ms; TE, 75, FOV 160 mm and slice thickness 3 mm);
the region of interests (ROI), was placed on lesion to measure
ADC values. ADC maps obtained from DW images at b0,
b500 and b1000 s/mm2 gradients.
Lesions were assessed by using ESUR/PI-RADS criteria for
DWI, T2WI, DCE-MRI, and by using the sum of these scores.
Zonal dominant parameters corresponding to the score ofFig. 1 ROC curve for the sensitivity and speciﬁcity of Mp-MRI
with PI-RAD2.0 scoring system.
Table 3 DWI with ADC values in 37 PZ lesions and T2WI in 18TZ lesions with DCEMRI ﬁndings and PI-RAD2 scoring system.
PI-RAD score DW PZ ﬁnding No & % T2 TZ ﬁnding No & %
1 No abnormality 4 (10,8) No abnormality 6 (33.3)
2 Indistinct area on ADC map 3 (8.1) Well deﬁned hypo-intense/heterogonous 5 (27.7)
3 Moderate diﬀusion restriction 6 (16.3) Heterogonous with obscured margin 3 (16.7)
4 Marked diﬀusion restriction 16 (43.2) Non circumscribed hypo-heterogeneous 1 (5.6)
5 >1.5 cm with marked RD or invasive behavior 8 (21.6) >1.5 cm non circumscribed or invasive behavior 3 (16.7)
ADC Malignant (0.89 ± 0.24 lm2/m 30 (81) 30 (81)
P < 0.001 Benign (1.34 ± 0.21 lm2/ms) 7 (19)
DCEMRI
Positive Malignant 28 PZ 8 TZ 65.5%
Negative Benign 9 PZ 10 34.5%
Fig. 2 62yrs old patient, with felt P/R hard suspicious prostate nodule, (a and b) DWI and ADC map revealed nodular lesion at the
anterior aspect of PZ with signiﬁcant diffusion restitution, ADC value measuring ‘‘0.8763”, (c and d) DCE-MRI revealed moderate
enhancement with type III enhancement curve). PI-RADS 2.0, score = 4. All MP-MRI ﬁndings are collectively diagnostic of Malignant
lesion. Histo-pathology: Adeno-Ca. (Gleason score 8).
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lated. PI-RAD V2 classiﬁcation was used to deﬁne the total
summation of the different Mp-MRI ﬁndings (DWI, T2,
CDE) for differentiation between malignant and benign pro-
static lesions (8).1.4. Lesion assessment
All the lesions were evaluated by two radiologists; all patients
underwent TR U/S biopsy from the detected MRI focal lesion,
shortly after the MRI examination (at a period ranging from
Fig. 3 73 yrs old patient, C/O: enlarged prostate with suspicious nodular gland felt by P/R (a) T2WI, showed non-homogenous texture
with no deﬁnite well deﬁned focal lesion, (b and c) DCE-MRI revealed gradual enhancement with persistent rising type I enhancement
curve. All MP-MRI ﬁndings are diagnostic of Benign prostatic lesion: PI-RADS 2.0 score = 1, Histo-pathology: Benign prostate
hypertrophy, no malignancy.
Fig. 4 57 yrs old patient, with hard suspicious Rt. prostatic nodule felt by at P/R examination. (a) T2WI, showed a non-homogenous
poorly deﬁned focal area at the Rt. sided TZ lesion (red circle). (b and c) DCE-MRI revealed early enhancement with type II enhancement
curve. PI-RADS 2.0, score = 4 All MP-MRI ﬁndings are collectively diagnostic of Malignant lesion, Histo-pathology: Adeno-Ca.
(Gleason score 7).
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during a single session. The prostate was divided into 18
regions for purposes of review, 12 in the PZ and 6 in the TZ.
First, the readers assigned a PI-RADS 2.0 score to each region.
Brieﬂy, this system entails assignment of a separate score from1 to 5 to each region for each of the DW imaging, T2-weighted
imaging, and DCE MRI sequences. For DCE MR images, a
binary scale was used (0 = no focal early enhancement;
1 = presence of early focal enhancement). In addition, the
overall score consisted of the score for the dominant sequence
Fig. 5 71 yrs old patient, with hard suspicious Rt. prostatic nodule felt by P/R (a and b) DWI and ADC map revealed moderate
diffusion restriction at Rt. side peripheral zone lesion (red circle), ADC value ‘‘0.958.93”, (c and d) DCE-MRI revealed mild enhancement
with type II enhancement curve. PI-RADS 2.0 score = 3. All MP-MRI ﬁndings are collectively diagnostic of mostly Malignant lesion.
Histo-pathology: Adeno-Ca. (Gleason score 8).
Assessment of the accuracy of multi-parametric MRI 1079(DWI for PZ lesions and T2-weighted for TZ lesions) plus one
point added to the overall score for DCE MR imaging results
that were positive for cancer, but only if the addition of the one
point converted the PI-RADS 2.0 score from 3 to 4 (8).
1.5. Histopathologic examination
The prostatic biopsy was ﬁxed in 4% buffered formaldehyde
for approximately 48 h and was handled according to local
clinical histopathologic routines for diagnostic purposes. A
pathologist with more than 13 years of experience who was
blinded to the imaging results examined the hematoxylin-
eosin and saffron–stained slides, outlined cancer foci and
described cancer location, and determined the cancer grade
according to the Gleason grading system; Higher grade pros-
tate cancer was deﬁned as lesions showing a primary Gleason
score pattern of 4 or higher (9) (Tables 1 and 2).
1.6. Statistical analysis
Data entry and analysis were done using the program Statisti-
cal Package for the Social Sciences (SPSS). Quantitative data
were presented by mean and standard deviation, while qualita-
tive data were presented by frequency distribution. The ADC
values between malignant and benign groups were comparedusing Mann–Whitney test. P< 0.05 was considered statisti-
cally signiﬁcant. The sensitivity, speciﬁcity, negative and posi-
tive predictive values (PPV) were assessed. Also, the ROC
curve analysis was performed.
2. Results
Out of the 55 lesions included in this study, 38 lesions proved
to be malignant: 30 lesions in the PZ and 8 in the TZ (Histo-
path: Adenocarcinoma), while 17 lesions proved to be benign
prostatic lesions; 7 in the PZ and 10 in the TZ (Histo-path;
11 benign prostate hypertrophy, 4 adenoma and 2 prostatitis)
(Tables 1 and 2).
Mp-MRI (DWI with ADC value measurements for PZ
lesions (37)) followed by Post Gad dynamic MRI ﬁndings
and PI-RAD2 scoring of the included prostatic suspicious
lesions:-
I- DWI:-it showed focal moderate-marked diffusion restric-
tion (scores 3 and 4) in 22 (6 and 16) lesions while score 5 was
given to 8 lesions more than 1.5 cm or with invasive behavior;
Mean ADC value was 0.89 ± 0.24 lm2/ms for the lesions that
proved to be malignant (see Fig. 1).
No abnormality/hypo-intense areas at ADC map were
noted in 7 benign lesions. The ADC values of benign prostatic
lesions were 1.34 ± 0.21 lm2/ms which were statistically
Fig. 6 66 yrs old patient with hard suspicious Lt. prostatic nodule at P/R examination. (a) DWI showed a moderate diffusion restriction
of the lesion (red circle), (b) ADC map revealed, ADC value ‘‘0.641”, (c and d) DCE-MRI revealed early moderate enhancement (red
circle),with type II enhancement curve). The total PI-RADS 2.0 score given to this lesion, was = 4. All Mp-MRI ﬁndings are collectively
diagnostic of Malignant lesion. Histo-pathology: Adeno-Ca. (Gleason score 8).
Table 4 Sensitivity, speciﬁcity and accuracy of Mp-MRI with
PI-RADS 2.0 in diagnosis of prostatic focal lesions.
Sensitivity 92.11%
Speciﬁcity 94.12%
+ve predictive value 97.22%
Accuracy 92.727%
1080 H.A.E-K.A. El-Samei et al.signiﬁcantly higher than those of malignant lesion (P< 0.001)
(Table 3).
II-DCE-MRI, revealed focal enhancing lesion that showed
early enhancement and early washout (+ve) in 28 lesions.
Adding DCE MRI to DWI score in the 6 lesions with score
3 in lesions raises it to score 4 in 4/6 lesions that aid in the diag-
nosis of malignant lesions.
No enhancement/gradual rising enhancement pattern (ve)
was noted in 9 (7 benign and 2 indeterminate) lesions (Table 3,
Figs. 2, 5 and 6).
Mp-MRI (T2 for TZ lesions) (10) followed by Post Gad
dynamic MRI ﬁndings and PI-RAD2 scoring of the included
prostatic suspicious lesions:-
I-T2WI of the TZ lesions detected 3 lesions that appeared
as ill-deﬁned heterogeneous signal intensity area (score 3)
and non-circumscribed hypo-heterogeneous area (score 4) in
1 lesion while lesions >1.5 cm or with invasive behavior diag-
nosed in 3 lesions.
Eleven lesions with benign score (1–2) that appeared as nor-
mal or well deﬁned hypo-intense/heterogeneous 6/5 lesions
were detected in T2 WI (Table 3).II-DCEMRI, revealed focal enhancing lesion that showed
early enhancement and early washout (+ve), in 8 lesions. Add-
ing DCE MRI to T2WI score in score 3 in lesions raises it to
score 4 in 2/3 lesions that aid in the diagnosis of malignant
lesions.
No enhancement/gradual enhancement pattern (-ve) was
noted in 10 lesions (Table 3, Figs. 3 and 4).
– The total PI-RAD 2.0 score of Mp-MRI for the 55 suspi-
cious prostatic lesions revealed 36 malignant lesions (scores,
4–5) and 16 benign lesions (scores 1–2) while indeterminate
lesions were 3 (score 3) that pathologically proved to be 2
malignant and 1 benign lesions.
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nosis of prostatic focal lesions using new PI-RADS score
were 92.11%, 94.12% and 92.7% respectively (Table 4).3. Discussion
Prostate MR imaging provides the potential to assist clinical
management of prostate cancer. Most recently, PI-RADS
standardized interpretation scheme that facilitates greater clin-
ical use of prostate MR imaging (11).
The histopathologic results were the gold slandered for this
work, it revealed 38 malignant ‘‘adenocarcinoma” and 17
benign lesions and the multi-parametric MRI examination of
the prostate was the selected technique for lesion evaluation.
This was concealed with Schlemmer et al. and Franiel who sta-
ted that the procedure of choice for diagnosing prostate cancer
is the multi-parametric MRI (12,13).
This work used Mp-MRI ﬁndings with PI-RAD score V2
to differentiate malignant from benign lesions of the prostatic.
For the PZ we considered DWI to be the primary determining
sequence (dominant technique), while for the TZ, T2W is the
primary determining sequence. This was in agreement with
Leonardo et al. who introduced the concept of a zonal domi-
nant parameter in an attempt to incorporate to ESUR/PI-
RADS criteria the performance of different techniques applied
to peripheral and transitional zone lesions (14). Also, Baur
et al. reported that assigning a PI-RADS score on the basis
of DWI for PZ lesions and a PI-RADS score on the basis of
T2-weighted imaging for TZ lesions was sufﬁcient for stratiﬁ-
cation of patients for further diagnostic workup (15).
For the 37 lesions located in PZ we considered DWI that
categorized 6 lesions with score 3, 16 lesions with score 4
and 8 lesions were given score 5; Mean ADC value was 0.89
± 0.24 lm2/ms for the lesions that proved to be malignant.
However, no abnormality/hypo-intense areas at ADC map
were noted in 7 benign lesions. The ADC values of benign pro-
static lesions were 1.34 ± 0.21 lm2/ms which were statistically
signiﬁcantly higher than that of malignant lesion (P< 0.001).
These results were in concordance with Zelhof et al. who
stated that on DWI, tumors appear hyperintense compared
to background due to the restricted water diffusion (16) and
with Koo et al. results that revealed signiﬁcant difference
between ADC values of normal prostate parenchyma and
prostate cancer (17). Noha et al. concluded that the addition
of the ADC map provides signiﬁcantly more accurate results
for prostate cancer detection and staging (18) and Meltem
et al., found that Mean ADC value of prostate cancer group
was signiﬁcantly lower than normal group (P= 0.001) (10).
Sato et al. found that ADC values of prostate cancer in both
peripheral and transition zones were signiﬁcantly lower than
those of benign tissue (19).
This study yielded that T2 WI of the detected 18 lesions in
the TZ, diagnosed 9 lesions to be likely malignant, 3 lesions
with score 3 while 4 lesions were given score 4 and 2 lesions
were given score 5. However, 9 lesions were likely benign with
1–2 score that was in agreement with Akin et al. who stated
that prostate cancer typically manifests as a round or ill-
deﬁned, T2 WI low signal intensity focus in the peripheral zone
(20) and with Sandeep et al. who concluded that T2W MRI is
critical in suggesting the location and extent of cancer which is
generally seen as low signal foci on the T2W MRI (21).DCE-MRI, revealed enhancing focal lesion that showed
positive results in 28 PZ lesions and 8 TZ lesions with curve
type 2–3 (+ve). Adding DCE MRI to DWI score in equivocal
PZ lesions raises it from score 3 to 4 in 4/6 lesions and to T2
score in equivocal TZ lesions raises its score from 3 to score
4 in 2/3 lesions that aid in the diagnosis of malignancy.
No enhancement/gradual rising enhancement pattern (ve)
was noted in 9 PZ lesions (7 benign and 2 indeterminate) and
in 10 TZ lesions (9 benign and 1 indeterminate).
These results matched with those of Meltem et al., who
found that the prostate cancers manifested with intense
enhancement at arterial phase and exhibited washout at late
phase on DCE MR images (10) and with Alonzi et al. and
Sciarra et al. who reported that early, rapid, and strong
enhancement with quick washout of contrast material is highly
suggestive of prostate cancer (22,23). Hara et al. showed that
DCEMRI is able to detect clinically important prostate cancer
in 93% of cases (24).
The total PI-RAD score V2 of Mp-MRI for the 55 suspi-
cious prostatic lesions revealed 36 malignant lesions (scores,
4–5) and 16 benign lesions (scores 1–2) while indeterminate
lesions were 3 (score 3) that pathologically proved to be 2
malignant and 1 benign lesions.
This matched results of other studies regarding the PI-
RADS classiﬁcation system which suggests high reliability
for Mp-MRI interpretation and its sum-score shows a strong
relation to tumor incidence and malignancy in the routine set-
ting for prostate cancer diagnosis (25,26). Sciarra et al. said
that: At present, Mp-MRI is the most sensitive and speciﬁc
imaging technique for localizing prostate cancer (27).
The statistical results of this study revealed that, Sensitivity,
Speciﬁcity and Accuracy of MP-MRI in diagnosis of prostatic
focal lesions using new PI-RAD2.0 score were, 92.11%,
94.12% and 92.7% respectively. This was in concordance with
results of Daniel who found that the sum PI-RAD score is reli-
able for cancer detection (sensitivity 90%, speciﬁcity 62%) (28)
and Alistair et al. found that 2 out of 88 men with Pi-RAD
score of 1 or 2 had signiﬁcant prostate cancer, giving a sensi-
tivity of 97% and a speciﬁcity of 60% at this threshold (29)
while Portalez et al. results showed that the sensitivity is
73.5%; speciﬁcity is 81.5%; and accuracy is 95.2% (26).4. Conclusion
PI-RAD V2 scoring of the Multi-parametric MRI, including
DWI with ADC measurements, T2WI added to DCE-MRI,
was proved to be a sensitive, non invasive and accurate tool
for characterization of prostatic focal lesions and distinguish-
ing between malignant and benign lesions.Conflict of interest
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